Most of us know someone who has been through breast cancer.
For many patients the first years on hormone-blocking pills go well, until the tumor finds a way around them. That stage of the disease has long been one of the hardest to treat.
On November 16, 2026, the FDA approved a new oral pill from Roche called Wilserdly, also known as giredestrant.
It is cleared for adults with advanced breast cancer that has picked up a specific genetic change making older hormone treatments stop working.
Also read: Parts of the brain appear to fall asleep in Parkinson's patients with hallucinations
The drug is taken once a day together with everolimus, another oral cancer pill.
It is approved for patients whose cancer is hormone receptor positive, HER2 negative, and carries a mutation in a gene called ESR1.
ESR1 mutations are one of the main reasons standard hormone therapy fails in advanced disease.
How the drug attacks a worn-out treatment target
Hormone receptor positive breast cancers rely on estrogen to grow. Standard pills called aromatase inhibitors try to starve the tumor by lowering estrogen in the body. Giredestrant works from the other side.
Also read: 9 signs your body may be running low on protein - and why the risk grows after 40
It binds to the estrogen receptor inside the tumor cell and tags it for destruction. Its class is called a selective estrogen receptor degrader, or SERD.
When a tumor picks up an ESR1 mutation, the receptor gets stuck in an active state and keeps firing even when estrogen is low. Giredestrant was designed to shut down that mutated receptor.
What the evERA trial showed
The approval rests on the Phase III evERA trial, published in The New England Journal of Medicine.
It enrolled 373 women and men with advanced hormone receptor positive, HER2 negative breast cancer, and 207 of them had ESR1-mutated tumors.
Also read: If you take iron supplements, these everyday foods and drinks may be blocking absorption
In that ESR1 group, patients on giredestrant plus everolimus went about 10 months before their cancer grew again.
On the comparator, a doctor's choice of hormone therapy plus everolimus, the figure was 5.5 months.
The risk of the cancer worsening or of death was cut by 62 percent.
The most common side effects were mouth sores, rash, fatigue, diarrhea, musculoskeletal pain, lung inflammation and nausea.
Also read: Eating strawberries every day may help ease period cramps, study suggests
Patients who develop new breathing problems, a lingering cough or painful mouth ulcers should flag them with their care team.
Why Roche is calling it a potential record seller
Roche has told investors the drug could become the company's biggest-ever product.
That is a bold claim for a company whose portfolio once included blockbusters like Herceptin and Avastin, which each brought in billions a year at their peak.
Analysts are not all convinced. Peak sales forecasts for Wilserdly span a wide range, from about 2.5 billion to 14.5 billion dollars a year, according to SWI swissinfo.ch.
Also read: Regular coffee drinking linked to a more active colon, researchers find
Roche has set the US list price at 22,500 dollars a month before discounts and rebates.
Patients should talk to their oncologist and insurer about whether the combination is a fit and what it will actually cost.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.
